Merck & Company Inc (MRK)vsTelix Pharmaceuticals Limited (TLX)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
TLX
Telix Pharmaceuticals Limited
$10.43
-0.10%
HEALTHCARE · Cap: $3.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 7988% more annual revenue ($65.01B vs $803.79M). MRK leads profitability with a 28.1% profit margin vs -0.9%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TLX
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+31.9%
Fair Value
$10.18
Current Price
$10.43
$0.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 49.3% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Trading at 8.5x book value
0.0% earnings growth
Distress zone — elevated risk
Operating margin of 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TLX
The strongest argument for TLX centers on Revenue Growth. Revenue growth of 49.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TLX
The primary concerns for TLX are Price/Book, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while TLX is a hypergrowth play — different risk/reward profiles.
TLX carries more volatility with a beta of 0.61 — expect wider price swings.
TLX is growing revenue faster at 49.3% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 27/100), backed by strong 28.1% margins. TLX offers better value entry with a 31.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Telix Pharmaceuticals Limited
HEALTHCARE · BIOTECHNOLOGY · USA
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?